Vanda Pharmaceuticals rebuffs unsolicited proposals from Future Pak LLC, citing undervaluation. Offers up to $7.75 per share. Board asserts resilient business with FDA-approved products. Future Pak urged to reconsider terms for fair shareholder value.
Edible Garden reported a preliminary first-quarter year-over-year increase in produce revenues of 40% and an increase in cut herb revenue of more than 200% compared to the same period last year. The company attributed the growth to its investments in equipment and infrastructure, as well as expanded retail distribution leading to a 12-fold increase in herb production.
Invo Bioscience reported $1.38 million in quarterly sales, representing a 396.15% increase over sales of $278,140 from the same period last year. The company also said it remains on-track with its goal of reaching break-even or profitability within its current operations in 2024.
CXApp shares are trading higher Wednesday after the company announced record double digit Annual Recurring Revenue (ARR) growth in the fourth quarter of 2023 and 24% ARR growth for the full year 2023. CXAI attributed the ARR growth to two large Fortune 1000 logo contracts in the fourth quarter that are slated for deployment in the summer of 2024, leveraging the CXAI platform and in partnership with Google Cloud.
Injective's (CRYPTO: INJ) price has increased 5.74% over the past 24 hours to $25.31, which is in the opposite direction of its trend over the past week, where it has experienced a 23.0% loss, moving from $32.69 to its current price.
Over the past 24 hours, Render's (CRYPTO: RNDR) price has fallen 5.23% to $7.6. This continues its negative trend over the past week where it has experienced a 15.0% loss, moving from $9.11 to its current price.